Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3

被引：0
|
作者：
van de Kerkhof, P. [1 ]
Guenther, L. [2 ]
Gottlieb, A. [3 ]
Sebastian, M. [4 ]
Wu, J. [5 ]
Foley, P. [6 ]
Morita, A. [7 ]
Goldblum, O. [8 ]
Zhang, L. [9 ]
Erickson, J. [9 ]
Ball, S. [9 ]
Rich, P. [10 ]
机构：
[1] Radboud Univ Nijmegan, Med Ctr, Nijmegen, Netherlands
[2] Guenther Dermatol Res Ctr, London, ON, Canada
[3] Tufts Med Ctr, Boston, MA USA
[4] Hautarztpraxis Mahlow, Blankenfelde Mahlow, Germany
[5] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[6] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[7] Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Oregon Hlth & Sci Univ, Ctr Hlth & Healing, Portland, OR 97201 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
fingernail psoriasis; ixekizumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P138
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [31] A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Kirkham, Bruce W.
    Egeberg, Alexander
    Behrens, Frank
    Pinter, Andreas
    Merola, Joseph F.
    Holzkaemper, Thorsten
    Gallo, Gaia
    Ng, Khai Jing
    Bolce, Rebecca
    Schuster, Christopher
    Nash, Peter
    Puig, Luis
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1127 - 1146
  • [32] A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Bruce W. Kirkham
    Alexander Egeberg
    Frank Behrens
    Andreas Pinter
    Joseph F. Merola
    Thorsten Holzkämper
    Gaia Gallo
    Khai Jing Ng
    Rebecca Bolce
    Christopher Schuster
    Peter Nash
    Luis Puig
    Rheumatology and Therapy, 2023, 10 : 1127 - 1146
  • [33] Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS
    Seyger, M. M. B.
    Reich, A.
    El Baou, C.
    Schuster, C.
    Riedl, E.
    Paller, A. S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : E911 - E913
  • [34] Ixekizumab achieved and sustained nail psoriasis resolution regardless of disease severity through 5 years: Results from Uncover-3
    Egeberg, Alexander
    Kristensen, Lars Erik
    Vender, Ronald
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB74 - AB74
  • [35] Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S
    Bagel, Jerry
    Gottlieb, Alice B.
    Burge, Russel
    See, Kyoungah
    Garrelts, Alyssa
    McKean-Matthews, Missy
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB82 - AB82
  • [36] Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis
    Langley, Richard G.
    Williams, David
    Papp, Kim
    Olds, Michele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [37] Ixekizumab treatment shows a neutral impact on the glucose and lipid profile of patients with moderate-to-severe psoriasis: Results from UNCOVER-1,-2, and-3
    Wu, J. J.
    Egeberg, A.
    Solomon, J. A.
    Osuntokun, O.
    Goldblum, O.
    Moriarty, S.
    Zhao, F.
    Korman, N.
    Vincent, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [38] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
    Merola, Joseph F.
    Elewski, Boni
    Tatulych, Svitlana
    Lan, Shuping
    Tallman, Anna
    Kaur, Mandeep
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 79 - +
  • [39] Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate to severe psoriasis: 24-week results from a multicenter, randomized, open-label, rater-blinded study (SPIRIT-H2H)
    Smith, Saxon D.
    Kristensen, Lars Erik
    Schusters, Christopher
    Sapin, Christophe
    Leage, Soyi Liu
    Riedl, Elisabeth
    Reich, Kristian
    Rich, Phoebe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB12 - AB12
  • [40] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
12345